Inhibition of Japanese encephalitis virus entry into the cells by the envelope glycoprotein domain III (EDIII) and the loop3 peptide derived from EDIII

Antiviral Res. 2012 May;94(2):179-83. doi: 10.1016/j.antiviral.2012.03.002. Epub 2012 Mar 10.

Abstract

Japanese encephalitis virus (JEV) infection is a major cause of acute viral encephalitis both in humans and animals. The domain III of virus envelope protein (EDIII) plays important roles in interacting with host cell receptors to facilitate virus entry. In this study, recombinant JEV EDIII was expressed and purified. The protein showed the ability to inhibit JEV infection in BHK-21 cells with 50% inhibition at a concentration of 25μg/ml. Based on NMR structure of JEV EDIII, we chose several loop peptides that were reported to be related to receptor binding to test their possible inhibitory activities on virus infection. Our in vitro experiments demonstrated that one of the loop peptides (loop3) can prevent JEV infection with 50% inhibition at concentration of 10μM by interfering in virus attachment to the cells. Our in vivo experiments on mice showed the loop3 was the most protective peptide when administered before virus challenge. Therefore, the loop3 peptide may be served as basis for the development of novel antiviral agents against Japanese encephalitis virus or other flaviviruses infection.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antiviral Agents / administration & dosage*
  • Antiviral Agents / pharmacology
  • Cell Line
  • Cricetinae
  • Disease Models, Animal
  • Encephalitis Virus, Japanese / drug effects*
  • Encephalitis Virus, Japanese / genetics
  • Encephalitis Virus, Japanese / physiology
  • Encephalitis, Japanese / prevention & control
  • Glycoproteins / genetics
  • Glycoproteins / metabolism
  • Inhibitory Concentration 50
  • Mice
  • Microbial Sensitivity Tests
  • Peptides / administration & dosage*
  • Peptides / genetics
  • Peptides / pharmacology
  • Treatment Outcome
  • Viral Envelope Proteins / genetics
  • Viral Envelope Proteins / metabolism*
  • Virus Internalization / drug effects*

Substances

  • Antiviral Agents
  • Glycoproteins
  • Peptides
  • Viral Envelope Proteins